PUBMED FOR HANDHELDS

Journal Abstract Search


195 related items for PubMed ID: 29492674

  • 1. Urinary CD80: a biomarker for a favorable response to corticosteroids in minimal change disease.
    Cara-Fuentes G, Lanaspa MA, Garcia GE, Banks M, Garin EH, Johnson RJ.
    Pediatr Nephrol; 2018 Jul; 33(7):1101-1103. PubMed ID: 29492674
    [Abstract] [Full Text] [Related]

  • 2. Urinary CD80 as a Replacement for Renal Biopsy for Diagnosis of Pediatric Minimal Change Disease.
    Ahmed HM, Ezzat DA, Doudar NA, Adel M.
    Iran J Kidney Dis; 2018 Mar; 12(2):107-111. PubMed ID: 29507273
    [Abstract] [Full Text] [Related]

  • 3. Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome.
    Mishra OP, Kumar R, Narayan G, Srivastava P, Abhinay A, Prasad R, Singh A, Batra VV.
    Pediatr Nephrol; 2017 Aug; 32(8):1355-1361. PubMed ID: 28210837
    [Abstract] [Full Text] [Related]

  • 4. The utility of urinary CD80 as a diagnostic marker in patients with renal diseases.
    Minamikawa S, Nozu K, Maeta S, Yamamura T, Nakanishi K, Fujimura J, Horinouchi T, Nagano C, Sakakibara N, Nagase H, Shima H, Noda K, Ninchoji T, Kaito H, Iijima K.
    Sci Rep; 2018 Nov 23; 8(1):17322. PubMed ID: 30470792
    [Abstract] [Full Text] [Related]

  • 5. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse.
    Cara-Fuentes G, Venkatareddy M, Verma R, Segarra A, Cleuren AC, Martínez-Ramos A, Johnson RJ, Garg P.
    Pediatr Nephrol; 2020 Oct 23; 35(10):1887-1896. PubMed ID: 32399663
    [Abstract] [Full Text] [Related]

  • 6. Patients with primary focal segmental glomerulosclerosis with detectable urinary CD80 are more similar to patients with minimal change disease in clinicopathological features.
    Gong X, Huang J, Zhang Y, Wang F, Wang X, Meng L, Cheng X, Liu G, Cui Z, Zhao M.
    Ren Fail; 2023 Oct 23; 45(2):2279642. PubMed ID: 37942512
    [Abstract] [Full Text] [Related]

  • 7. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
    Cara-Fuentes G, Wei C, Segarra A, Ishimoto T, Rivard C, Johnson RJ, Reiser J, Garin EH.
    Pediatr Nephrol; 2014 Aug 23; 29(8):1363-71. PubMed ID: 24263531
    [Abstract] [Full Text] [Related]

  • 8. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
    Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G.
    Am J Physiol Renal Physiol; 2016 Mar 01; 310(5):F335-41. PubMed ID: 26697986
    [Abstract] [Full Text] [Related]

  • 9. Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis?
    Cara-Fuentes G, Wasserfall CH, Wang H, Johnson RJ, Garin EH.
    Pediatr Nephrol; 2014 Dec 01; 29(12):2333-40. PubMed ID: 25017621
    [Abstract] [Full Text] [Related]

  • 10. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.
    Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, Johnson RJ.
    Kidney Int; 2010 Aug 01; 78(3):296-302. PubMed ID: 20485332
    [Abstract] [Full Text] [Related]

  • 11. CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood.
    Eroglu FK, Orhan D, İnözü M, Duzova A, Gulhan B, Ozaltin F, Topaloglu R.
    Pediatr Int; 2019 Dec 01; 61(12):1250-1256. PubMed ID: 31513327
    [Abstract] [Full Text] [Related]

  • 12. Urinary CD80 excretion is a predictor of good outcome in children with primary nephrotic syndrome.
    Ling C, Liu X, Shen Y, Chen Z, Fan J, Jiang Y, Meng Q.
    Pediatr Nephrol; 2018 Jul 01; 33(7):1183-1187. PubMed ID: 29569191
    [Abstract] [Full Text] [Related]

  • 13. Minimal change disease: a CD80 podocytopathy?
    Ishimoto T, Shimada M, Araya CE, Huskey J, Garin EH, Johnson RJ.
    Semin Nephrol; 2011 Jul 01; 31(4):320-5. PubMed ID: 21839364
    [Abstract] [Full Text] [Related]

  • 14. Urinary CD80 levels as a diagnostic biomarker of minimal change disease.
    Ling C, Liu X, Shen Y, Chen Z, Fan J, Jiang Y, Meng Q.
    Pediatr Nephrol; 2015 Feb 01; 30(2):309-16. PubMed ID: 25142334
    [Abstract] [Full Text] [Related]

  • 15. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.
    Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, Johnson RJ.
    Pediatr Nephrol; 2015 Mar 01; 30(3):469-77. PubMed ID: 25239302
    [Abstract] [Full Text] [Related]

  • 16. The role of B7-1 in proteinuria of glomerular origin.
    Novelli R, Benigni A, Remuzzi G.
    Nat Rev Nephrol; 2018 Sep 01; 14(9):589-596. PubMed ID: 29959373
    [Abstract] [Full Text] [Related]

  • 17. CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.
    Teh YM, Lim SK, Jusoh N, Osman K, Mualif SA.
    Biomed Res Int; 2021 Sep 01; 2021():6671552. PubMed ID: 33506028
    [Abstract] [Full Text] [Related]

  • 18. Urinary cytokines and steroid responsiveness in idiopathic nephrotic syndrome of childhood.
    Woroniecki RP, Shatat IF, Supe K, Du Z, Kaskel FJ.
    Am J Nephrol; 2008 Sep 01; 28(1):83-90. PubMed ID: 17914249
    [Abstract] [Full Text] [Related]

  • 19. Serum from minimal change patients in relapse increases CD80 expression in cultured podocytes.
    Ishimoto T, Cara-Fuentes G, Wang H, Shimada M, Wasserfall CH, Winter WE, Rivard CJ, Araya CE, Saleem MA, Mathieson PW, Johnson RJ, Garin EH.
    Pediatr Nephrol; 2013 Sep 01; 28(9):1803-12. PubMed ID: 23689904
    [Abstract] [Full Text] [Related]

  • 20. Minimal change disease: a "two-hit" podocyte immune disorder?
    Shimada M, Araya C, Rivard C, Ishimoto T, Johnson RJ, Garin EH.
    Pediatr Nephrol; 2011 Apr 01; 26(4):645-9. PubMed ID: 21052729
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.